{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:24:06Z","timestamp":1787167446833,"version":"build-2736575974"},"reference-count":25,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,7,13]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>The short treatment regimen (STR) achieves a &gt;80% cure in rifampicin-resistant tuberculosis (RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first study to evaluate the replacement of injectables by linezolid in patients with audiometry abnormalities at baseline or during the treatment.<\/jats:p>\n                  <jats:p>We conducted a retrospective cohort study of all RR-TB patients started on the STR between 2016 and June, 2019, in Niger. Patients underwent audiometry every 2\u2005months in 2016 and every month since 2017.<\/jats:p>\n                  <jats:p>Of 195 patients, 16.9% (33 out of 195) received linezolid from the start (n=17), or switched from injectables to linezolid during treatment (n=16), based on audiometry abnormalities. In 2016, two patients developed severe ototoxicity despite switching to linezolid. Since 2017, no patient developed severe hearing loss or complete deafness. Severe haematological toxicity was observed in 18.1% (six out of 33) of patients on linezolid, none of which was life threatening. The use of linezolid was associated with severe but manageable adverse events (hazard ratio 8.9, 95% CI 2.5\u201331.5; p=0.001). A total of 90.9% (30 out of 33) of patients on a linezolid-containing STR were cured, and none experienced treatment failure. Three died, but not due to adverse events.<\/jats:p>\n                  <jats:p>Baseline and monthly audiometry monitoring and using linezolid after detection of hearing abnormalities appears effective to prevent severe ototoxicity, while keeping high treatment success and manageable adverse events.<\/jats:p>","DOI":"10.1183\/13993003.02250-2020","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T16:49:41Z","timestamp":1595522981000},"page":"2002250","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss"],"prefix":"10.1183","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-1994","authenticated-orcid":false,"given":"Mahamadou Bassirou","family":"Souleymane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-3126","authenticated-orcid":false,"given":"Alberto","family":"Piubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Mamane","family":"Lawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-5660","authenticated-orcid":false,"given":"Souleymane","family":"Hassane-Harouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourtala Mohamed","family":"Assao-Neino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphazazi","family":"Soumana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelika","family":"Hamidou-Harouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assiatou","family":"Gagara-Issoufou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer","family":"Ortu\u00f1o-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Roggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Schwoebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efdou","family":"Mamadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7183-4895","authenticated-orcid":false,"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1017-4675","authenticated-orcid":false,"given":"Bouke","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Van Deun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-1484","authenticated-orcid":false,"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"2024102101530210000_57.1.2002250.1","unstructured":"World Health Organization . Global tuberculosis report 2019. World Health Organization Document 2019; WHO\/CDS\/TB\/2019.15:1-283."},{"key":"2024102101530210000_57.1.2002250.2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/jcm9010055","article-title":"Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence","volume":"9","author":"Tr\u00e9bucq","year":"2019","journal-title":"J Clin Med"},{"key":"2024102101530210000_57.1.2002250.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"2024102101530210000_57.1.2002250.4","doi-asserted-by":"crossref","first-page":"105844","DOI":"10.1016\/j.rmed.2019.105844","article-title":"Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements","volume":"161","author":"Piubello","year":"2020","journal-title":"Respir Med"},{"key":"2024102101530210000_57.1.2002250.5","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0535"},{"key":"2024102101530210000_57.1.2002250.6","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.eclinm.2020.100268","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schwoebel","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2024102101530210000_57.1.2002250.7","unstructured":"World Health Organization . Rapid Communication: key changes to the treatment of drug-resistant tuberculosis. Geneva, World Health Organization, 2019."},{"key":"2024102101530210000_57.1.2002250.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00061-2017"},{"key":"2024102101530210000_57.1.2002250.9","unstructured":"World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization Document 2019; WHO\/CDS\/TB\/2019.3:1-99."},{"key":"2024102101530210000_57.1.2002250.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"2024102101530210000_57.1.2002250.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00145014"},{"key":"2024102101530210000_57.1.2002250.12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5588\/ijtld.17.0871","article-title":"Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger","volume":"23","author":"Harouna","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102101530210000_57.1.2002250.13","unstructured":"Challenge TB . Audiometry in the Management of Drug-Resistant Tuberculosis. 2017."},{"key":"2024102101530210000_57.1.2002250.14","unstructured":"World Health Organization . Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014). World Health Organization Document 2013; WHO\/HTM\/TB\/2013.2:1-40."},{"key":"2024102101530210000_57.1.2002250.15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimcrob"},{"key":"2024102101530210000_57.1.2002250.16","unstructured":"Agence publique fran\u00e7aise de recherches sur le sida et les h\u00e9patites virales . Echelle ANRS de cotation de la gravit\u00e9 des \u00e9v\u00e9nements ind\u00e9sirables chez l'adulte. Version n.1.0-2008 (Translation of the French version n.6\u20132003)."},{"key":"2024102101530210000_57.1.2002250.17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102101530210000_57.1.2002250.18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5588\/ijtld.17.0830","article-title":"Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection","volume":"22","author":"Hong","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102101530210000_57.1.2002250.19","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0498"},{"key":"2024102101530210000_57.1.2002250.20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102101530210000_57.1.2002250.21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102101530210000_57.1.2002250.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01522-2019"},{"key":"2024102101530210000_57.1.2002250.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02383-2019"},{"key":"2024102101530210000_57.1.2002250.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2024102101530210000_57.1.2002250.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1815121"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02250-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:35:55Z","timestamp":1740364555000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02250-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,21]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1183\/13993003.02250-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02250-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}